Lexeo Therapeutics

Lexeo Therapeutics EBIT

The EBIT of Lexeo Therapeutics (LXEO) as of Nov 4, 2026 is -109.26 M USD. In the previous year, EBIT was -105.77 M USD — a change of 3.30% (lower).

EBIT

-109.26 MUSD

YoY

3.30%

Last updated:

In 2025, Lexeo Therapeutics's EBIT was -109.26 M USD, a 3.30% increase from the -105.77 M USD EBIT recorded in the previous year.

The Lexeo Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-68.51 M USD
Jan 1, 2024
-105.77 M USD
Jan 1, 2025
-109.26 M USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
-71.72 M USD
Jan 1, 2028 (e)
-67.84 M USD
Jan 1, 2029 (e)
40.80 M USD
Jan 1, 2030 (e)
222.36 M USD
The Lexeo Therapeutics EBIT history
YEAREBITYoY
est222.36 MUSD+444.94%
est40.80 MUSD-160.15%
est-67.84 MUSD-5.41%
est-71.72 MUSD—
est0.00USD-100.00%
-109.26 MUSD+3.30%
-105.77 MUSD+54.37%
-68.51 MUSD+13.23%
-60.51 MUSD+19.50%
-50.64 MUSD+1,003.73%
-4.59 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexeo Therapeutics Revenue

Lexeo Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-68.51 M USD
-66.39 M USD
Jan 1, 2024
0.00 USD
-105.77 M USD
-98.33 M USD
Jan 1, 2025
0.00 USD
-109.26 M USD
-99.96 M USD
Jan 1, 2026 (e)
0.00 USD
0.00 USD
-87.49 M USD
Jan 1, 2027 (e)
0.00 USD
-71.72 M USD
-100.19 M USD
Jan 1, 2028 (e)
46.53 M USD
-67.84 M USD
-87.90 M USD
Jan 1, 2029 (e)
238.46 M USD
40.80 M USD
43.67 M USD
Jan 1, 2030 (e)
575.37 M USD
222.36 M USD
238.82 M USD

Lexeo Therapeutics Margins

Lexeo Therapeutics stock margins

The Lexeo Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lexeo Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lexeo Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
0.00 %
- %
Jan 1, 2027 (e)
100.00 %
- %
- %
Jan 1, 2028 (e)
100.00 %
-145.82 %
-188.93 %
Jan 1, 2029 (e)
100.00 %
17.11 %
18.31 %
Jan 1, 2030 (e)
100.00 %
38.65 %
41.51 %

Lexeo Therapeutics Stock analysis

What does Lexeo Therapeutics do? Lexeo Therapeutics Inc develops gene therapy candidates for rare cardiovascular diseases with unmet medical needs. The company focuses on four programs: LX2006 targets Friedreich’s ataxia cardiomyopathy by delivering functional frataxin, LX2020 treats PKP2-ACM through intravenous delivery of PKP2 gene, LX2021 addresses inherited cardiac disorders via connexin 43 protein delivery, and LX2022 delivers TNNI3 gene for hypertrophic cardiomyopathy. These therapies aim to modify disease progression by addressing genetic causes rather than symptoms. Lexeo generates revenue through potential future sales of approved gene therapies and partnerships with pharmaceutical companies for development and commercialization. The primary buyers are healthcare providers and hospitals treating patients with rare genetic cardiovascular conditions. Lexeo’s clinical-stage therapies target specific genetic disorders where no approved treatments exist. The company’s strategy involves advancing these candidates through clinical trials to secure regulatory approvals. Revenue streams include milestone payments from partners upon achieving development and regulatory milestones, as well as potential royalties on future product sales. The key segments served are patients with Friedreich’s ataxia, PKP2-ACM, inherited cardiac muscle disorders, and hypertrophic cardiomyopathy. Lexeo collaborates with healthcare systems and specialized medical centers to reach these patient populations. The company’s products are designed to treat the underlying genetic causes of rare cardiovascular diseases. LX2006, LX2020, LX2021, and LX2022 represent distinct therapeutic approaches for different genetic conditions. Lexeo’s business model relies on securing partnerships with larger pharmaceutical firms for co-development and commercialization. These partnerships provide upfront payments and milestone-based funding during clinical development. The target market consists of patients with rare genetic cardiovascular diseases who lack effective treatment options. Lexeo Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Lexeo Therapeutics's EBIT

Lexeo Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Lexeo Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Lexeo Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Lexeo Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Lexeo Therapeutics stock

EBIT of Lexeo Therapeutics is -109.26 M USD in 2025.

EBIT of Lexeo Therapeutics changed from -105.77 M USD to -109.26 M USD, representing a 3.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Lexeo Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Lexeo Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lexeo Therapeutics

All Key Metrics — Lexeo Therapeutics